J&J Strikes Deal with Biotech Startup for Alzheimer’s Treatment

Johnson and Johnson’s Innovation Center will fund early R&D efforts for one of drug startup Alector’s targets, with the option to negotiate a commercial agreement if the startup can show proof of concept.

Alector is based at the Janssen Labs @QB3 innovation lab in San Francisco. The specifics about the monoclonal antibody being developed have not been disclosed, but  the early stage exploratory program has potential to enhance J&J's Alzheimer’s pipeline.

Read more at Med City News

More News:

All news »

What are your comments?

You cannot post comments until you have logged in. Login Here.

Comments

No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments